Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $4.6 million.

  • Xeris Biopharma Holdings' Change in Accured Expenses rose 88464.82% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 6756.63%. This contributed to the annual value of $3.6 million for FY2024, which is 16233.99% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Change in Accured Expenses of $4.6 million as of Q3 2025, which was up 88464.82% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Change in Accured Expenses peaked at $7.9 million during Q4 2021, and registered a low of -$13.9 million during Q1 2023.
  • For the 5-year period, Xeris Biopharma Holdings' Change in Accured Expenses averaged around $18684.2, with its median value being $1.2 million (2022).
  • The largest annual percentage gain for Xeris Biopharma Holdings' Change in Accured Expenses in the last 5 years was 88464.82% (2025), contrasted with its biggest fall of 66411.4% (2025).
  • Xeris Biopharma Holdings' Change in Accured Expenses (Quarter) stood at $7.9 million in 2021, then tumbled by 90.5% to $751000.0 in 2022, then skyrocketed by 718.91% to $6.1 million in 2023, then plummeted by 78.02% to $1.4 million in 2024, then surged by 241.57% to $4.6 million in 2025.
  • Its Change in Accured Expenses was $4.6 million in Q3 2025, compared to $5.4 million in Q2 2025 and -$8.6 million in Q1 2025.